H.C. Wainwright reiterates Buy rating on Neumora Therapeutics stock

Neumora Therapeutics (NMRA) received a reiterated "Buy" rating and $18.00 price target from H.C. Wainwright, despite a 90% year-to-date stock decline and a Q1 2025 net loss of $68 million. The biopharmaceutical company initiated a Phase 1 study for NMRA-861, a new lead schizophrenia candidate replacing a prior one due to preclinical safety concerns, with data anticipated in Q1 2026. While facing Nasdaq delisting risk and proposing a reverse stock split, Neumora secured a $125 million debt facility, extending its cash runway into 2027, as it progresses its neuroscience pipeline.

Analysis

Neumora Therapeutics (NMRA) presents a high-risk, high-reward profile for a clinical-stage biopharmaceutical company, characterized by conflicting fundamental signals. On one hand, the company is advancing its pipeline by initiating a Phase 1 study for a new lead schizophrenia candidate, NMRA-861, with data expected in Q1 2026. This follows the discontinuation of a prior candidate due to preclinical safety concerns, and management is positioning its pipeline as a potential "two molecule" franchise. A key positive development is the securing of a $125 million debt facility, extending its cash runway into 2027, which provides critical funding to reach several clinical data readouts across its programs in late 2025 and early 2026. This financial buffer is crucial given the company's widening Q1 net loss, which increased to $68 million from $53.7 million year-over-year. On the other hand, the company faces severe headwinds, evidenced by a 90% year-to-date stock price decline and a Nasdaq delisting risk for failing to meet the minimum bid price requirement. The proposed reverse stock split to regain compliance is a significant red flag. The reiterated "Buy" rating and an $18 price target from H.C. Wainwright stand in stark contrast to the market's current valuation and the stock's performance, highlighting the speculative nature of the investment thesis, which hinges entirely on future clinical success.

Key Decisions for Investors

• Investors should weigh the significant long-term potential of the new NMRA-861 candidate and a cash runway extended to 2027 against the immediate and substantial risks of share price delisting and a potential reverse stock split.
• The most critical catalysts to monitor are the upcoming clinical data readouts for the COASTAL and NMRA-511 studies by early 2026, and especially the Phase 1 data for NMRA-861 expected in Q1 2026.
• Consider the wide disparity between the analyst price target of $18.00 and the stock's severe underperformance as an indicator of the market's deep skepticism, suggesting any position should be sized according to a high tolerance for risk and potential for total loss.
• The widening quarterly net loss, despite the new debt facility, underscores the company's high cash burn rate, a key metric to track for a pre-revenue biotech firm.